Will the PTAB be a Road Block for Biotech? Lessons Learned from the First Three Years of Inter-Partes Review and Future Prospects

2:15-3:15 PM PT | June 7, 2016 | San Francisco

MBHB Partner Kevin Noonan, Ph.D. is a featured speaker at a 2016 BIO panel presentation entitled, “Will the PTAB be a Road Block for Biotech? Lessons Learned from the First Three Years of Inter-Partes Review and Future Prospects,” set for 2:15-3:15 PM PT on June 7 in San Francisco.

Description:

Inter-partes review proceedings before the Patent Trial and Appeal Board (PTAB) have transformed patent practice and unsettled expectations for patent holders while empowering patent challengers. In the first three years of this practice, the Board has invalidated patent claims and entire patents with such frequency that some see the proceedings as a road block for patents. Most of the affected patents have been outside the biotech and pharma area but recently patents on these technologies have also been subject to IPR with greater frequency. As the PTAB has developed procedures for instituting and holding IPR proceedings there has developed a belief that some of those practices be modified, including the standard used for claim construction and the ability of a patent holder to amend claims during proceedings. This panel will explore these issues and proposals for change in the context of using IPRs as an adjunct to biosmilars litigation under the Biologics Price Competition and Innovation Act. Anticipated CLE Credit: 1.0 (may vary based on which jurisdiction requested) CLE Credits will be awarded for this session, pending state approval in Virginia and California. Attendees will be asked to fill out a sign-in sheet at the session and will receive a certificate of attendance after the conference. (Session ID: 9694)